nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—SLC6A2—sympathetic nervous system—adrenal gland cancer	0.0838	0.182	CbGeAlD
Atomoxetine—HTR2A—sympathetic nervous system—adrenal gland cancer	0.0504	0.11	CbGeAlD
Atomoxetine—HTR2A—vein—adrenal gland cancer	0.0471	0.103	CbGeAlD
Atomoxetine—CYP2C19—urine—adrenal gland cancer	0.0432	0.0941	CbGeAlD
Atomoxetine—NPY1R—adrenal cortex—adrenal gland cancer	0.0358	0.078	CbGeAlD
Atomoxetine—NPY1R—gonad—adrenal gland cancer	0.0297	0.0646	CbGeAlD
Atomoxetine—NPY1R—pituitary gland—adrenal gland cancer	0.029	0.0631	CbGeAlD
Atomoxetine—HTR2A—urine—adrenal gland cancer	0.0276	0.0601	CbGeAlD
Atomoxetine—NPY1R—adrenal gland—adrenal gland cancer	0.0259	0.0563	CbGeAlD
Atomoxetine—CYP3A4—urine—adrenal gland cancer	0.0256	0.0556	CbGeAlD
Atomoxetine—CYP2D6—urine—adrenal gland cancer	0.0251	0.0548	CbGeAlD
Atomoxetine—SLC6A2—gonad—adrenal gland cancer	0.0101	0.0219	CbGeAlD
Atomoxetine—SLC6A2—adrenal gland—adrenal gland cancer	0.00878	0.0191	CbGeAlD
Atomoxetine—Reboxetine—ABCB1—adrenal gland cancer	0.00608	0.165	CrCbGaD
Atomoxetine—HTR2A—gonad—adrenal gland cancer	0.00606	0.0132	CbGeAlD
Atomoxetine—HTR2A—pituitary gland—adrenal gland cancer	0.00591	0.0129	CbGeAlD
Atomoxetine—Protriptyline—ABCB1—adrenal gland cancer	0.00558	0.151	CrCbGaD
Atomoxetine—Fenoprofen—PTGS2—adrenal gland cancer	0.00534	0.145	CrCbGaD
Atomoxetine—HTR2A—adrenal gland—adrenal gland cancer	0.00528	0.0115	CbGeAlD
Atomoxetine—Fluoxetine—ABCB1—adrenal gland cancer	0.00381	0.103	CrCbGaD
Atomoxetine—Maprotiline—ABCB1—adrenal gland cancer	0.00356	0.0964	CrCbGaD
Atomoxetine—Propafenone—ABCB1—adrenal gland cancer	0.0034	0.092	CrCbGaD
Atomoxetine—Ketoprofen—PTGS2—adrenal gland cancer	0.00315	0.0854	CrCbGaD
Atomoxetine—Propranolol—ABCB1—adrenal gland cancer	0.00233	0.063	CrCbGaD
Atomoxetine—Methadone—ABCB1—adrenal gland cancer	0.00191	0.0517	CrCbGaD
Atomoxetine—Desipramine—ABCB1—adrenal gland cancer	0.00176	0.0477	CrCbGaD
Atomoxetine—NPY1R—Signaling by GPCR—GNAS—adrenal gland cancer	0.00138	0.00274	CbGpPWpGaD
Atomoxetine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00135	0.00269	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00133	0.00264	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MEN1—adrenal gland cancer	0.00132	0.00261	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—TSHR—adrenal gland cancer	0.00126	0.00249	CbGpPWpGaD
Atomoxetine—CYP2C19—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	0.00125	0.00248	CbGpPWpGaD
Atomoxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00125	0.00247	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00122	0.00243	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00121	0.00239	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	0.00116	0.0023	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00115	0.00229	CbGpPWpGaD
Atomoxetine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.0011	0.00218	CbGpPWpGaD
Atomoxetine—HTR1D—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00109	0.00217	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—TSHR—adrenal gland cancer	0.00109	0.00216	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00108	0.00214	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00107	0.00213	CbGpPWpGaD
Atomoxetine—HTR1B—G alpha (i) signalling events—POMC—adrenal gland cancer	0.00107	0.00213	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00105	0.00208	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00105	0.00208	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—POMC—adrenal gland cancer	0.00102	0.00203	CbGpPWpGaD
Atomoxetine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00101	0.002	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PRKACA—adrenal gland cancer	0.00101	0.002	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—BRAF—adrenal gland cancer	0.001	0.00199	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—GNAS—adrenal gland cancer	0.000991	0.00197	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—GNAS—adrenal gland cancer	0.000984	0.00195	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000981	0.00195	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000974	0.00193	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNRHR—adrenal gland cancer	0.000968	0.00192	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—GNAS—adrenal gland cancer	0.000963	0.00191	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000963	0.00191	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNRHR—adrenal gland cancer	0.00096	0.00191	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000956	0.0019	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000954	0.00189	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNRHR—adrenal gland cancer	0.00094	0.00187	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000936	0.00186	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—POMC—adrenal gland cancer	0.000929	0.00184	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.0009	0.00179	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000893	0.00177	CbGpPWpGaD
Atomoxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000877	0.00174	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TSHR—adrenal gland cancer	0.000875	0.00174	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000874	0.00173	CbGpPWpGaD
Atomoxetine—HTR1D—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00087	0.00173	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TSHR—adrenal gland cancer	0.000868	0.00172	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	0.000865	0.00172	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CDC42—adrenal gland cancer	0.000853	0.00169	CbGpPWpGaD
Atomoxetine—HTR1B—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000852	0.00169	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TSHR—adrenal gland cancer	0.00085	0.00169	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000846	0.00168	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000839	0.00167	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000822	0.00163	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IGF2—adrenal gland cancer	0.000822	0.00163	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—GNAS—adrenal gland cancer	0.000815	0.00162	CbGpPWpGaD
Atomoxetine—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.000815	0.00162	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.000796	0.00158	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IGF1R—adrenal gland cancer	0.000795	0.00158	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—BRAF—adrenal gland cancer	0.000768	0.00152	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—PRKACA—adrenal gland cancer	0.000766	0.00152	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—GNAS—adrenal gland cancer	0.00073	0.00145	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000723	0.00143	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNRHR—adrenal gland cancer	0.000713	0.00141	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000709	0.00141	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	0.000701	0.00139	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—adrenal gland cancer	0.000698	0.00139	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.000691	0.00137	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	0.000688	0.00137	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TERT—adrenal gland cancer	0.000684	0.00136	CbGpPWpGaD
Atomoxetine—HTR6—GPCR ligand binding—POMC—adrenal gland cancer	0.000667	0.00132	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000662	0.00131	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR ligand binding—POMC—adrenal gland cancer	0.000662	0.00131	CbGpPWpGaD
Atomoxetine—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00066	0.00131	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR ligand binding—POMC—adrenal gland cancer	0.000649	0.00129	CbGpPWpGaD
Atomoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000646	0.00128	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TSHR—adrenal gland cancer	0.000644	0.00128	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—GNAS—adrenal gland cancer	0.000634	0.00126	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—adrenal gland cancer	0.00063	0.00125	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000628	0.00125	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNRH1—adrenal gland cancer	0.000628	0.00125	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000623	0.00124	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000623	0.00124	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—GNAS—adrenal gland cancer	0.000621	0.00123	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNRHR—adrenal gland cancer	0.000619	0.00123	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—TSHR—adrenal gland cancer	0.000616	0.00122	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00061	0.00121	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ABCB1—adrenal gland cancer	0.000609	0.00121	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—BAD—adrenal gland cancer	0.000595	0.00118	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000586	0.00116	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—POMC—adrenal gland cancer	0.000583	0.00116	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000582	0.00115	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNRH1—adrenal gland cancer	0.00058	0.00115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.000575	0.00114	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNRH1—adrenal gland cancer	0.000575	0.00114	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00057	0.00113	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNRH1—adrenal gland cancer	0.000563	0.00112	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.000563	0.00112	CbGpPWpGaD
Atomoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.000561	0.00111	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00056	0.00111	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TSHR—adrenal gland cancer	0.000559	0.00111	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000556	0.0011	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—POMC—adrenal gland cancer	0.000549	0.00109	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000544	0.00108	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—BRAF—adrenal gland cancer	0.000542	0.00108	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—ZNRF3—adrenal gland cancer	0.000541	0.00107	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	0.000536	0.00106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CDC42—adrenal gland cancer	0.000532	0.00106	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SPRY2—adrenal gland cancer	0.00053	0.00105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CDC42—adrenal gland cancer	0.000528	0.00105	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SPRY2—adrenal gland cancer	0.000526	0.00104	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EGFR—adrenal gland cancer	0.000525	0.00104	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SDHB—adrenal gland cancer	0.000522	0.00104	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CDC42—adrenal gland cancer	0.000517	0.00103	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TSHR—adrenal gland cancer	0.000517	0.00103	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SPRY2—adrenal gland cancer	0.000515	0.00102	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TSHR—adrenal gland cancer	0.000513	0.00102	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GNAS—adrenal gland cancer	0.000509	0.00101	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GNAS—adrenal gland cancer	0.000505	0.001	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TSHR—adrenal gland cancer	0.000502	0.000996	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GNAS—adrenal gland cancer	0.000494	0.000981	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.000493	0.000978	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR ligand binding—POMC—adrenal gland cancer	0.000492	0.000976	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MEN1—adrenal gland cancer	0.000486	0.000964	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MEN1—adrenal gland cancer	0.000482	0.000957	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SDHB—adrenal gland cancer	0.00048	0.000952	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MEN1—adrenal gland cancer	0.000472	0.000937	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000462	0.000917	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000432	0.000857	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.000428	0.00085	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNRH1—adrenal gland cancer	0.000427	0.000847	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—POMC—adrenal gland cancer	0.000427	0.000847	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000413	0.000819	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.00041	0.000815	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PRKACA—adrenal gland cancer	0.000401	0.000797	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CDC42—adrenal gland cancer	0.000392	0.000778	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000392	0.000777	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPRY2—adrenal gland cancer	0.00039	0.000775	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TSHR—adrenal gland cancer	0.00038	0.000755	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—POMC—adrenal gland cancer	0.000377	0.000749	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CDC42—adrenal gland cancer	0.000375	0.000744	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GNAS—adrenal gland cancer	0.000375	0.000744	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—POMC—adrenal gland cancer	0.000374	0.000743	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PRKACA—adrenal gland cancer	0.000371	0.000736	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNRH1—adrenal gland cancer	0.000371	0.000736	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PRKACA—adrenal gland cancer	0.000368	0.00073	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—POMC—adrenal gland cancer	0.000367	0.000728	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PRKACA—adrenal gland cancer	0.00036	0.000715	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GNAS—adrenal gland cancer	0.000358	0.000711	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MEN1—adrenal gland cancer	0.000358	0.00071	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	0.000351	0.000696	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—POMC—adrenal gland cancer	0.000343	0.00068	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CDC42—adrenal gland cancer	0.00034	0.000676	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—POMC—adrenal gland cancer	0.00034	0.000675	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPRY2—adrenal gland cancer	0.000339	0.000673	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—SDHD—adrenal gland cancer	0.000336	0.000667	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RRM1—adrenal gland cancer	0.000336	0.000667	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—POMC—adrenal gland cancer	0.000333	0.000661	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TSHR—adrenal gland cancer	0.00033	0.000656	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GNAS—adrenal gland cancer	0.000325	0.000646	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CDC42—adrenal gland cancer	0.000315	0.000624	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SDHB—adrenal gland cancer	0.000314	0.000622	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CDC42—adrenal gland cancer	0.000312	0.00062	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MEN1—adrenal gland cancer	0.000311	0.000617	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—adrenal gland cancer	0.00031	0.000616	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RRM1—adrenal gland cancer	0.000309	0.000613	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—SDHD—adrenal gland cancer	0.000309	0.000613	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CDC42—adrenal gland cancer	0.000306	0.000607	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF2—adrenal gland cancer	0.000303	0.000602	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF2—adrenal gland cancer	0.000301	0.000597	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GNAS—adrenal gland cancer	0.000301	0.000597	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GNAS—adrenal gland cancer	0.000298	0.000592	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF2—adrenal gland cancer	0.000295	0.000585	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IGF1R—adrenal gland cancer	0.000293	0.000582	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GNAS—adrenal gland cancer	0.000292	0.00058	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IGF1R—adrenal gland cancer	0.000291	0.000577	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IGF1R—adrenal gland cancer	0.000285	0.000565	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—adrenal gland cancer	0.000278	0.000551	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PRKACA—adrenal gland cancer	0.000273	0.000542	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—adrenal gland cancer	0.00026	0.000517	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TERT—adrenal gland cancer	0.000252	0.000501	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—adrenal gland cancer	0.000252	0.000501	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—MED12—adrenal gland cancer	0.000251	0.000497	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TERT—adrenal gland cancer	0.00025	0.000497	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TERT—adrenal gland cancer	0.000245	0.000487	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—adrenal gland cancer	0.000241	0.000479	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PRKACA—adrenal gland cancer	0.000237	0.000471	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CDC42—adrenal gland cancer	0.000232	0.00046	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—MED12—adrenal gland cancer	0.00023	0.000457	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.000224	0.000445	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF2—adrenal gland cancer	0.000223	0.000443	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GNAS—adrenal gland cancer	0.000221	0.000439	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BAD—adrenal gland cancer	0.00022	0.000436	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—adrenal gland cancer	0.000219	0.000435	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BAD—adrenal gland cancer	0.000218	0.000432	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IGF1R—adrenal gland cancer	0.000216	0.000428	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BAD—adrenal gland cancer	0.000213	0.000423	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—adrenal gland cancer	0.000202	0.000402	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RRM1—adrenal gland cancer	0.000202	0.000401	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SDHD—adrenal gland cancer	0.000202	0.000401	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CDC42—adrenal gland cancer	0.000201	0.000399	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—adrenal gland cancer	0.000201	0.000399	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—BRAF—adrenal gland cancer	0.0002	0.000397	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—BRAF—adrenal gland cancer	0.000198	0.000394	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—adrenal gland cancer	0.000197	0.00039	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—BRAF—adrenal gland cancer	0.000194	0.000385	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF2—adrenal gland cancer	0.000194	0.000385	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—adrenal gland cancer	0.000194	0.000384	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—adrenal gland cancer	0.000192	0.000381	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GNAS—adrenal gland cancer	0.000192	0.000381	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—adrenal gland cancer	0.000188	0.000374	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IGF1R—adrenal gland cancer	0.000187	0.000372	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TERT—adrenal gland cancer	0.000186	0.000369	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PRKACA—adrenal gland cancer	0.000183	0.000363	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	0.000179	0.000355	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	0.000168	0.000334	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BAD—adrenal gland cancer	0.000162	0.000321	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TERT—adrenal gland cancer	0.000161	0.00032	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—MED12—adrenal gland cancer	0.000151	0.000299	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—adrenal gland cancer	0.000149	0.000296	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GNAS—adrenal gland cancer	0.000148	0.000294	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—BRAF—adrenal gland cancer	0.000147	0.000292	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ABCB1—adrenal gland cancer	0.000145	0.000289	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000144	0.000287	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000143	0.000284	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—adrenal gland cancer	0.000143	0.000283	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BAD—adrenal gland cancer	0.00014	0.000279	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CTNNB1—adrenal gland cancer	0.00014	0.000279	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GNAS—adrenal gland cancer	0.000136	0.00027	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	0.000134	0.000265	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—adrenal gland cancer	0.000129	0.000257	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—BRAF—adrenal gland cancer	0.000128	0.000254	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—adrenal gland cancer	0.000124	0.000246	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—adrenal gland cancer	0.000114	0.000227	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—adrenal gland cancer	0.000114	0.000225	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—adrenal gland cancer	0.000111	0.000221	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	0.00011	0.000218	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000106	0.000211	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—adrenal gland cancer	9.97e-05	0.000198	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—adrenal gland cancer	9.61e-05	0.000191	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—adrenal gland cancer	9.53e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—adrenal gland cancer	9.33e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CTNNB1—adrenal gland cancer	9.24e-05	0.000183	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—adrenal gland cancer	9.17e-05	0.000182	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GNAS—adrenal gland cancer	8.91e-05	0.000177	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	8.74e-05	0.000174	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—adrenal gland cancer	8.43e-05	0.000167	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—adrenal gland cancer	7.96e-05	0.000158	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	7.32e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—adrenal gland cancer	7.32e-05	0.000145	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—adrenal gland cancer	7.07e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—adrenal gland cancer	6.14e-05	0.000122	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—adrenal gland cancer	6e-05	0.000119	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	4.78e-05	9.5e-05	CbGpPWpGaD
